专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009101479A2 FC RECEPTOR-BINDING POLYPEPTIDES WITH MODIFIED EFFECTOR FUNCTIONS 审中-公开
标题翻译：具有改良效应功能的FC受体结合多肽
公开(公告)号：WO2009101479A2
公开(公告)日：2009-08-20
申请号：PCT/IB2008003978
申请日：2008-05-14
申请人： NOVIMMUNE SA , ELSON GREG , LEGER OLIVIER
发明人： ELSON GREG , LEGER OLIVIER
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/52 , C07K2317/71
摘要： Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.
摘要翻译：公开了用于产生具有修饰的人Fcγ受体IIA（CD32A）结合特征的变体多肽（例如抗体）的方法，导致促炎介质的增加的抑制，同时通过其Fv部分保留与靶抗原的结合，该方法包括改变多肽通过取代选自SAAF，SKAF，NAAF和NKAF的序列的人IgG CH2区域的EU位置325,326或328处的至少两个氨基酸残基。还公开了分子，特别是多肽，更特别是包括变体CDR3区的免疫球蛋白（例如抗体），其中变体CDR3区包括相对于野生型CDR3区修饰的至少一个氨基酸。可以根据本发明的方法产生的多肽是高度可变的，并且它们可以包括含有Fc区或其生物活性部分的抗体和融合蛋白。

2. 发明申请

WO2006109191A2 ANTI-INTERFERON GAMMA ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗干扰素抗体及其使用方法
公开(公告)号：WO2006109191A2
公开(公告)日：2006-10-19
申请号：PCT/IB2006/001514
申请日：2006-01-27
申请人： NOVIMMUNE S.A. , FERLIN, Walter , FISCHER, Nicolas , ELSON, Greg , LEGER, Olivier
发明人： FERLIN, Walter , FISCHER, Nicolas , ELSON, Greg , LEGER, Olivier
CPC分类号： C07K16/249 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hlFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFNγ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune- related disorders and in the amelioration of a symptom associated with an immune-related disorder.
摘要翻译：本发明涉及与人类干扰素γ（hIFN1β）结合的完全人抗体及其片段，从而调节IFNα 和其受体IFNγ-R，和/或调节IFNα的生物学活性。本发明还涉及使用这种抗-IFN？抗体在预防或治疗免疫相关疾病和改善与免疫相关病症相关的症状中。

3. 发明申请

WO2005065015A3 NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2005065015A3
公开(公告)日：2005-07-21
申请号：PCT/IB2004/004433
申请日：2004-12-10
申请人： NOVIMMUNE SA , ELSON, Greg, Christopher, Andrew
发明人： ELSON, Greg, Christopher, Andrew
IPC分类号： C07K16/28
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.

4. 发明申请

WO2005065015A2 NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：中和抗体及其使用方法
公开(公告)号：WO2005065015A2
公开(公告)日：2005-07-21
申请号：PCT/IB2004004433
申请日：2004-12-10
申请人： NOVIMMUNE SA , ELSON GREG CHRISTOPHER ANDREW
发明人： ELSON GREG CHRISTOPHER ANDREW
IPC分类号： A61K38/17 , A61K39/395 , A61P11/06 , A61P19/02 , A61P31/00 , A61P37/00 , C07K14/705 , C07K16/28 , C07K19/00 , C12N5/10 , C12N15/10 , C12N15/79 , G01N33/50
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/705 , C07K2317/24 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体和识别TLR4 / MD2复合物以及不与MD-2复合时的TLR4的单克隆抗体。本发明进一步提供了使用单克隆抗体作为治疗剂的方法。本发明还提供了可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及使用可溶性嵌合蛋白作为治疗剂的方法，用于筛选测定和抗体生产。

5. 发明申请

WO2013149111A2 ANTI-TLR4 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗TLR4抗体及其用途
公开(公告)号：WO2013149111A2
公开(公告)日：2013-10-03
申请号：PCT/US2013/034543
申请日：2013-03-29
申请人： NOVIMMUNE S.A. , ROUSSEAU, Francois , LOYAU, Jérémy , FISCHER, Nicolas , ELSON, Greg , KOSCO-VILBOIS, Marie
发明人： ROUSSEAU, Francois , LOYAU, Jérémy , FISCHER, Nicolas , ELSON, Greg , KOSCO-VILBOIS, Marie
IPC分类号： C07K16/28
CPC分类号： C07K16/2896 , C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要： Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
摘要翻译：公开了特异性结合Toll样受体4（TLR-4）的抗体，以及使用抗TLR4抗体作为治疗剂和诊断剂的方法。

6. 发明申请

WO2009101479A3 FC RECEPTOR-BINDING POLYPEPTIDES WITH MODIFIED EFFECTOR FUNCTIONS 审中-公开
公开(公告)号：WO2009101479A3
公开(公告)日：2009-08-20
申请号：PCT/IB2008/003978
申请日：2008-05-14
申请人： NOVIMMUNE SA , ELSON, Greg , LEGER, Olivier
发明人： ELSON, Greg , LEGER, Olivier
IPC分类号： A61K39/395 , A61P29/00
摘要： Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.

7. 发明申请

WO2007110678A2 NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：中和抗体及其使用方法
公开(公告)号：WO2007110678A2
公开(公告)日：2007-10-04
申请号：PCT/IB2005/004206
申请日：2005-06-14
申请人： NOVIMMUNE S.A. , ELSON, Greg , LEGER, Olivier
发明人： ELSON, Greg , LEGER, Olivier
IPC分类号： C07K16/00
CPC分类号： C07K16/2896 , A61K38/00 , A61K38/1709 , A61K38/177 , A61K39/0005 , A61K2039/505 , A61K2039/575 , C07K14/47 , C07K14/70596 , C07K16/18 , C07K2317/24 , C07K2317/32 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2319/00
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物以及TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

8. 发明申请

WO2005118635A2 ANTI-CD3 ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译：抗CD3抗体及其使用方法
公开(公告)号：WO2005118635A2
公开(公告)日：2005-12-15
申请号：PCT/US2005/019922
申请日：2005-06-03
申请人： NOVIMMUNE S.A. , MACH, Bernard , DEAN, Yann , KOSCO-VILBOIS, Marie , ELSON, Greg, Christopher, Andrew , FISCHER, Nicolas , LEGER, Olivier
发明人： MACH, Bernard , DEAN, Yann , KOSCO-VILBOIS, Marie , ELSON, Greg, Christopher, Andrew , FISCHER, Nicolas , LEGER, Olivier
IPC分类号： C07K14/47
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/74
摘要： The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR’s), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要翻译：本发明涉及针对抗原CD3的抗体和这种抗体的用途。特别地，本发明提供了完全针对CD3的人单克隆抗体。编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是包含重链和轻链免疫球蛋白分子的序列，特别是对应于跨越框架区和/或互补决定区的连续重链和轻链序列的序列（CDR ），特别是FR1至FR4或CDR1至CDR3。还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

9. 发明申请

WO2013088259A3 METHODS OF PURIFYING ANTIBODIES 审中-公开
标题翻译：纯化抗体的方法
公开(公告)号：WO2013088259A3
公开(公告)日：2013-11-14
申请号：PCT/IB2012003028
申请日：2012-10-19
申请人： NOVIMMUNE SA , ELSON GREG , FOUQUE NICOLAS , DEPOISIER JEAN-FRANCOIS , FISCHER NICOLAS , MAGISTRELLI GIOVANNI
发明人： ELSON GREG , FOUQUE NICOLAS , DEPOISIER JEAN-FRANCOIS , FISCHER NICOLAS , MAGISTRELLI GIOVANNI
IPC分类号： C07K16/00 , C07K16/46
CPC分类号： C07K16/00 , C07K16/248 , C07K16/249 , C07K16/2866 , C07K16/468 , C07K2317/32 , C07K2317/52
摘要： The invention provides methods of purifying antibodies using various antibody- specific purification media to rapidly and efficiently separate mixtures of antibodies, antibody fragments and/or antibody components to isolate a desired antibody product from the mixture. The invention relates to the purification of bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule, e.g., antibodies composed of a single heavy chain and two different light chains, one containing Kappa constant domain and the other a Lambda constant domain, including antibodies of different specificities that share a common heavy chain. The invention also provides the methods of efficiently purifying intact antibodies by separating the intact antibody from non-intact antibodies including free light chains.
摘要翻译：本发明提供了使用各种抗体特异性纯化介质来纯化抗体以快速且有效地分离抗体，抗体片段和/或抗体组分的混合物以从混合物中分离出所需抗体产物的方法。本发明涉及纯化对免疫球蛋白分子的每个结合位点具有不同特异性的双特异性单克隆抗体，例如由单一重链和两个不同轻链组成的抗体，一个含有κ恒定结构域，另一个含有λ恒定结构域包括具有共同重链的不同特异性的抗体。本发明还提供了通过将完整抗体与包括游离轻链的非完整抗体分开来有效纯化完整抗体的方法。

10. 发明申请

WO2010041145A3 IL-17-MEDIATED TRANSFECTION METHODS 审中-公开
公开(公告)号：WO2010041145A3
公开(公告)日：2010-04-15
申请号：PCT/IB2009/007235
申请日：2009-10-07
申请人： NOVIMMUNE SA , ELSON, Greg , CONTIE, Mathias , FOUQUE, Nicolas , LEGER, Olivier , POITEVIN, Yves
发明人： ELSON, Greg , CONTIE, Mathias , FOUQUE, Nicolas , LEGER, Olivier , POITEVIN, Yves
IPC分类号： C07K14/54 , C12N15/00
摘要： The invention comprises compositions and methods for IL-17-mediated transfection that results in superior and enhanced properties of cell survival and protein production.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式